Archive: December 2023

Addressing Unmet Need in the Management of Patients With ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer: Clinician’s Perspective

Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]

Novel Combination Approaches to Locoregional and Systemic Therapy in the Management of Primary and Metastatic Liver Tumors

Abstract: Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways […]

Breakthroughs in Cancer Care

On rare occasions, we witness a true breakthrough in the treatment of cancer. I remember when Druker and colleagues published their phase 1 results with imatinib […]

Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy

H&O  Which patients with early-stage non–small cell lung cancer (NSCLC) are eligible for surgical resection? HW  We perform surgical resection in nearly all patients with stage […]

Update on the CAPTIVATE Trial of Ibrutinib Plus Venetoclax

H&O  Could you describe the impetus for and design of the CAPTIVATE trial? TS  The large, multicenter, phase 2 CAPTIVATE trial focused on patients with chronic […]

The National Cancer Institute’s Clinical Trials Innovation Unit

H&O  What is the National Cancer Institute’s (NCI’s) Clinical Trials Innovation Unit (CTIU), why was it established, and what are its goals? MJM  The CTIU is […]

Preventing Infectious Complications in Chronic Lymphocytic Leukemia

H&O  What causes the elevated risk of infections in patients with chronic lymphocytic leukemia (CLL)? CS  Immunologic defects in patients with CLL are caused by the […]

EGFR Inhibitor Rechallenge in Metastatic Colorectal Cancer

H&O  How often do patients with colorectal cancer (CRC) develop metastatic disease? JG  Most CRC patients present with stage 1, 2, or 3 disease, with only […]

Back to Archive